1
Treatment of Mature B-cell Lymphoma/Leukaemia
Condition(s):B-Cell LymphomaLast Updated:March 28, 2012Completed
LMB C: 26 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients
Condition(s):B-cell Non Hodgkin Lymphoma; Mature B-cell Leukemia Burkitt-typeLast Updated:June 14, 2017Unknown status
3
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Condition(s):Neoplasms With Mesothelin Expression; Epithelioid Mesothelioma; Cholangiocarcinoma, Extrahepatic; Adenocarcinoma, PancreaticLast Updated:August 1, 2023Completed
4
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Condition(s):Neoplasms; Pancreatic NeoplasmsLast Updated:March 15, 2022Completed
5
Treatment for Advanced B-Cell Lymphoma
Condition(s):Diffuse Large Cell Lymphoma; Burkitt’s Lymphoma; High Grade B-cell LymphomaLast Updated:October 25, 2022Completed
6
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
Condition(s):Malignant Pleural Mesotheliomas (Mpm); Malignant Pleural Effusions (Mpe); Epithelial Tumors, Malignant; Pleural Effusions, Malignant; Mesothelin (Msln)Last Updated:September 25, 2023Recruiting
7
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Condition(s):MesotheliomaLast Updated:August 23, 2022Completed
8
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Condition(s):MesotheliomaLast Updated:September 6, 2023Recruiting
9
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Condition(s):MesotheliomaLast Updated:November 22, 2019Terminated
10
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Condition(s):MesotheliomaLast Updated:December 2, 2021Terminated